Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

BACKGROUND: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progress using MEK inhibitors following disea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2011
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3237573/
https://ncbi.nlm.nih.gov/pubmed/22194965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0028973
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares